Drugs · acquisition-cost intelligence
Dexmethylphenidate Hydrochloride Extended-Release
dexmethylphenidate hydrochloride· ingredient dexmethylphenidateCentrally acting sympathomimetics· DEXMETHYLPHENIDATE HYDROCHLORIDE 10 mg/1; DEXMETHYLPHENIDATE HYDROCHLORIDE 15 mg/1; DEXMETHYLPHENIDATE HYDROCHLORIDE 20 mg/1; DEXMETHYLPHENIDATE HYDROCHLORIDE 25 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$1.93
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 11 weeks.
2025-07-232026-05-20
Same-ingredient options by acquisition cost
Other dexmethylphenidate products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Focalin | $0.31366 | −$1.62 |
| Dexmethylphenidate Hydrochloride Extended-Release | $1.28 | −$0.65460 |
| Dexmethylphenidate hydrochloride | $2.08 | +$0.14840 |
Medicare Part D coverage · CY2026
On 56 plan formularies · typical tier 4
Prior auth 2% · Step therapy 0% · Quantity limit 80% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.